Exclusion
- Unacceptable toxicity on prior anti-PD-1/PD-L1 treatment.
- Active leptomeningeal disease or uncontrolled brain metastasis.
- Active autoimmune diseases or history of autoimmune diseases that may relapse.
- Any active malignancy ≤ 2 years
- Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before first dose of study drugs
- History of interstitial lung disease, noninfectious pneumonitis or uncontrolled diseases, including pulmonary fibrosis, acute lung diseases, etc.
8. Severe chronic or active infections (including tuberculosis infection, etc.) requiring systemic antibacterial, antifungal or antiviral therapy, within 14 days prior to first dose of study drugs
9. Known history of HIV infection
10. Patients with active hepatitis C infection.
11. Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drugs
12. Prior allogeneic stem cell transplantation or organ transplantation
13. Hypersensitivity to tislelizumab or sitravatinib, to any ingredient in the formulation, or to any component of the container
14. Bleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar agents requiring therapeutic INR monitoring within 6 months before first dose of study drugs
15. Concurrent participation in another therapeutic clinical trial